

# Oral administration of French maritime pine bark extract (Flavangenol<sup>®</sup>) improves clinical symptoms in photoaged facial skin

Minao Furumura<sup>1,2</sup>

Noriko Sato<sup>1</sup>

Nobutaka Kusaba<sup>3</sup>

Kinya Takagaki<sup>3</sup>

Juichiro Nakayama<sup>1</sup>

<sup>1</sup>Department of Dermatology, Fukuoka University School of Medicine, Fukuoka, <sup>2</sup>Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, <sup>3</sup>Toyo Shinyaku Co Ltd, Tosu City, Saga, Japan

**Background:** French maritime pine bark extract (PBE) has gained popularity as a dietary supplement in the treatment of various diseases due to its polyphenol-rich ingredients. Oligomeric proanthocyanidins (OPCs), a class of bioflavonoid complexes, are enriched in French maritime PBE and have antioxidant and anti-inflammatory activity. Previous studies have suggested that French maritime PBE helps reduce ultraviolet radiation damage to the skin and may protect human facial skin from symptoms of photoaging. To evaluate the clinical efficacy of French maritime PBE in the improvement of photodamaged facial skin, we conducted a randomized trial of oral supplementation with PBE.

**Methods:** One hundred and twelve women with mild to moderate photoaging of the skin were randomized to either a 12-week open trial regimen of 100 mg PBE supplementation once daily or to a parallel-group trial regimen of 40 mg PBE supplementation once daily.

**Results:** A significant decrease in clinical grading of skin photoaging scores was observed in both time courses of 100 mg daily and 40 mg daily PBE supplementation regimens. A significant reduction in the pigmentation of age spots was also demonstrated utilizing skin color measurements.

**Conclusion:** Clinically significant improvement in photodamaged skin could be achieved with PBE. Our findings confirm the efficacy and safety of PBE.

**Keywords:** polyphenols, pine bark extract, skin photoaging, antioxidants, antiaging

## Introduction

French maritime pine bark extract (*Pinus maritima*, PBE) is a complex mixture of bioflavonoids, with oligomeric proanthocyanidins (OPCs) as the major constituents. OPCs are dimers or oligomers of catechin, epicatechin, and their gallic acid esters. The major OPCs in PBE are proanthocyanidin B<sub>1</sub> (epicatechin-(4 $\beta$ →8)-catechin), catechin, and epicatechin.<sup>1</sup>

The process of concentrative extraction of OPCs from pine bark was established by Masquelier et al in 1948.<sup>2</sup> OPCs are found in a wide range of other plants, including common foods in an ordinary diet,<sup>3,4</sup> and are widely consumed as antioxidant supplements. Recent research has focused primarily on the clinical efficacy of PBE, including a wide range of cardiovascular benefits.<sup>5,6</sup> In addition to their antioxidant properties, PBE has been reported to lower blood pressure and to improve glycemic control, the lipid profile, fatty acid synthesis, and the peripheral circulation.<sup>7</sup>

Skin aging is accelerated on sun-exposed areas.<sup>8</sup> Solar ultraviolet radiation is a key factor in the photoaging process of human skin. Ultraviolet radiation generates reactive oxygen species (ROS) and thus leads to oxidative stress. To counteract

Correspondence: Minao Furumura  
Department of Dermatology, Kurume  
University School of Medicine and  
Kurume University Institute of Cutaneous  
Cell Biology, 67 Asahimachi, Kurume,  
Fukuoka, Japan 830-0011  
Tel +819 4231 7571  
Fax +819 4234 2620  
Email furumura\_minao@med.kurume-u.  
ac.jp

the harmful effects of oxidative damage by ROS, the skin is naturally equipped with ultraviolet inducible/adaptive antioxidant systems that have evolved to quench intracellular ROS, and consist of a variety of low molecular weight antioxidants (vitamins C and E) and intrinsic antioxidant enzymes for ROS-scavenging activity.<sup>9,10</sup> However, antioxidant mechanisms are not completely efficient and their limitations become gradually more pronounced during aging. The end result of this process is an imbalance in cellular redox homeostasis, causing indiscriminate oxidative damage to a wide range of biomolecules.<sup>11</sup> Oxidative stress induces proinflammatory cytokines, which in turn increase intracellular levels of ROS.<sup>12</sup> Consequently, there is an age-associated augmentation in both ROS production and in levels of oxidized/degraded proteins.<sup>13,14</sup>

Localized hyperpigmented lesions recognized as “age spots” are the most visible alterations in photoaged Asian skin.<sup>15</sup> They are clinically diagnosed as solar lentigines, and are frequently associated with mottled pigmentation and slight keratosis.<sup>16</sup> To date, almost all standard protocols for treating age spots are topical therapies.<sup>17,18</sup> Taking photoaging and ultraviolet defense mechanisms into consideration, an oral antioxidant treatment is thought to be an effective option. Orally administered vitamins or botanical polyphenols demonstrate ultraviolet-protective properties in the skin.<sup>19–21</sup> OPCs have been reported to be the strongest quenchers of ROS among the various antioxidants.<sup>22</sup> Therefore, PBE is expected to prevent photoaging and to improve the appearance of photodamaged skin.

PBE has been used as a food ingredient for thousands of years because of its safety and astringent taste. PBE and other OPC products, such as grape seed extracts, are now widely used as dietary supplements. Extensive research conducted with various formulations of PBE has already established its safety and tolerability for long-term human consumption.<sup>23</sup> However, an aqueous green tea extract supplement, which is another popular food source of polyphenols, has recently been reported to have the potential to induce liver failure.<sup>24,25</sup> Such adverse reactions appear to happen more often in European countries and in Canada, when high-dose green tea extracts are taken orally for a long time,<sup>26–29</sup> although green tea is consumed widely in Japan, China, and other Asian nations, and is becoming more popular in Western nations.

Taking these findings into consideration, in addition to dermatological testing of the efficacy of PBE, we characterized its hepatic safety and efficacy in the improvement of glycemic control and the plasma lipoprotein profile, as was recently shown in animal studies.<sup>30</sup> We performed total blood

assays, including liver function and cholesterol blood tests. The primary purpose of this study was to evaluate the clinical efficacy and safety of French maritime PBE for improvement of photodamaged facial skin in a randomized trial of oral supplementation with PBE.

## Materials and methods

### French maritime PBE

French maritime PBE (Flavangenol®) was provided by Toyo Shinyaku Inc, Tosu City, Saga, Japan. Flavangenol is a registered trademark in Japan, and the trademark Toyo-FVG® has been registered in the US.


### Patients

We enrolled 112 healthy women younger than 60 years with age spots, mostly diagnosed as solar lentigines, and multiple symptoms of photodamaged skin, including mottled pigmentation, roughness (including dry flaky skin), wrinkles, and swelling. All women enrolled in this study had mild to moderate facial photodamage graded on the Glogau scale between II and III and Fitzpatrick skin phototypes III to IV. After approval by the institutional ethics committee of Fukuoka University, which adheres to the principles of the Declaration of Helsinki, informed consent was obtained from all participants in the study. None of the subjects took topical/systemic retinoids, health food supplements, oral medications such as hormone replacement therapy, or topical medications, or were pregnant 4 weeks prior to enrolling in this study.

### Study design

Because of the seasonal fluctuation in daily doses of ultraviolet radiation, all clinical trials were started in December to minimize the influence of seasonal skin changes, such as sun tanning and the darkening of age spots due to environmental ultraviolet light exposure. In order to assess the time course of changes in photoaging scores, clinical assessments were conducted at baseline (study day 1) and every 4 weeks thereafter.

Twenty-four women were enrolled in an open-label, high-dose PBE trial and were treated with 100 mg/day PBE for 12 weeks, while a further 88 women were enrolled in part 1 of a separate low-dose trial and treated with PBE 40 mg/day for a total of 24 weeks in an open-label, randomized, parallel-group comparative fashion. The time course of the low-dose PBE trial is shown in Figure 1, in which randomization of subjects into groups 1 and 2 was performed using a computer-generated random number table. Allocation to



**Figure 1** Schematic outline of part 1 and part 2 of study using low-dose pine bark extract.

**Abbreviation:** PBE, pine bark extract.

group 1 or group 2 was done by opening the next sequentially numbered, sealed, opaque envelope. Group 1 participants were asked to take PBE 40 mg/day once daily, and to use a cleanser and sunscreen for 24 weeks throughout part 1 of the study. Group 2 participants were merely placed under observation without taking PBE for the first 12 weeks before starting oral treatment with PBE 40 mg/day once daily for the next 12 weeks, and were instructed to use a cleanser and sunscreen for 24 weeks throughout part 1 of the study.

We compared the improvement between subjects who received oral PBE for 24 weeks (group 1) and those who received only 12 weeks of treatment (group 2), corresponding to the latter half of the 24-week treatment period for group 1. At the end of part 1 of the low-dose study, 24 subjects were instructed to take PBE for a further 12 months (part 2 of the study) to evaluate the long-term efficacy and safety of PBE (Figure 1).

## Subjective assessments

The subjects completed a self-assessment questionnaire concerning their facial skin on a scale of 0 to 5 of increasing severity for the following criteria: pigmentation, wrinkles, roughness, dryness, and overall improvement. Each patient was asked to complete a self-assessment questionnaire at the final visit of each study, ie, after 12 weeks of treatment in the high-dose PBE trial or 24 weeks after completing part 1 of the low-dose trial. If a patient checked the “unknown” option, their results were excluded from statistical analysis.

Three board-certified dermatologists subjectively graded the subjects for clinical symptoms, ie, solar lentigines, mottled pigmentation, roughness (including dry/flaky skin), wrinkles, and swelling, based on a standardized assessment scale using photographs, after which an overall evaluation of the results was performed. All assessors remained unaware of subject treatment assignment throughout the trial.

## Objective measurements

At each visit, the melanin index of the age spots was evaluated using a method described in a previous report.<sup>31</sup> A colorimeter (CR-13, Konica-Minolta, Tokyo, Japan) was used to record facultative forehead skin color by calculating individual typology angle (ITA) degrees, as described elsewhere.<sup>32</sup> Fluctuation of facultative skin color was quantified in groups 1 and 2 during part 1 of the low-dose trial. In order to assess for any age-related decrease in epidermal keratinocyte turnover, we planimetrically measured the mean area of tape-stripped, basic fuchsin crystal violet-stained corneocytes by digital image analysis.

## Safety assessments

Fasting (10 hours) blood samples were collected from all enrolled subjects on day 0 and after 12 weeks (high-dose trial only), and at 24 weeks and 18 months from the start of the trials for routine hematology, blood chemistry, and urine investigations. A lipid panel measuring high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and free fatty acids was used to assess the plasma lipoprotein cholesterol profile. Routine hematology tests and examination of serum iron/ferritin levels were used to detect iron deficiency anemia. Aspartate aminotransferase and alanine aminotransferase levels were used to assess the safety of PBE with respect to its potential liver toxicity. Assessment of these tests was conducted by an outside laboratory (BML Inc, Tokyo, Japan). Body weight measurements and body fat percentage assessments were performed for all subjects in the low-dose trial.

## Data analysis

All statistical calculations were performed using StatView for Windows, version 5.0.1 (SAS Institute Inc, Cary, NC). The data are presented as the mean  $\pm$  standard deviation, unless otherwise specified. An unpaired *t*-test or Mann–Whitney U test was used to compare subjects when equal variance was shown by the F-test or when equal variance was not shown,

respectively. For clinical assessments, the Wilcoxon signed-rank test for related samples was used in a time course of trials, and the Mann–Whitney U test was used for comparing the two treatment groups. A two-tailed, independent *t*-test was performed for grading of clinical assessments, with *P* values noted. Either Dunnett's test or the Tukey–Kramer method was used to compare the means of the melanin index at each point during the observational study, with *P* values noted. Clinical laboratory test results were analyzed statistically using a Student's two-tailed paired *t*-test.

## Results

### Demographics

Twenty-four subjects aged 31–59 (mean  $36.9 \pm 6.6$ ) years completed 12 weeks of treatment with PBE 100 mg/day in the high-dose trial. Eighty-eight subjects enrolled into part 1 of the 24-week, low-dose, comparative study, and 77 (*n* = 38 in group 1, *n* = 39 in group 2) completed the 24-week treatment program and had data available for statistical analysis. The mean age at study entry was  $36.7 \pm 7.9$  years. The background details of the subjects are shown in Table 1. There was no significant difference in background features (age or facultative skin color) at study entry between the two groups, suggesting adequate randomization. There were no clinically meaningful differences in laboratory tests or body measurements at study entry. Eleven withdrawals occurred because of poor compliance, amongst which no adverse events were reported. Twenty-four subjects participated in the 18-month part 2 phase of the study, consisting of 15 subjects from group 1 and nine subjects from group 2 who completed the 24-week study and had long-term data available for statistical analysis. Their mean age at study entry was  $37.2 \pm 4.4$  years. Three dropouts occurred because of poor compliance, for whom no adverse events were reported.

### Subjective efficacy assessment

In the high-dose trial, the questionnaire survey about subjective facial symptoms showed that a relatively large number of subjects felt that their facial skin roughness, including dry skin, had improved (Table 2). Multiple digital image

**Table 1** Baseline demographics of randomized groups (phase I, low-dose PBE trial)

| Characteristics | Group I<br>N = 38 | Group II<br>N = 39 | P value |
|-----------------|-------------------|--------------------|---------|
| Age (yrs)       | 39.6 (8.3)        | 33.8 (6.5)         | 0.66    |
| ITA (degrees)   | 30.9 (8.3)        | 28.6 (5.4)         | 0.44    |

**Note:** Mean (SD).

**Abbreviations:** ITA, individual topology angle; PBE, pine bark extract.

**Table 2** Score assessments of questionnaire survey (high-dose PBE trial, N = 24)

| Symptoms                        | Improved | Unchanged | Aggravated |
|---------------------------------|----------|-----------|------------|
| Age spots                       | 7 (29)   | 16 (67)   | 1 (4)      |
| Wrinkles                        | 7 (29)   | 17 (71)   | 0 (0)      |
| Roughness (dry skin)            | 9 (38)   | 15 (63)   | 0 (0)      |
| Roughness (other than dry skin) | 13 (54)  | 9 (38)    | 2 (8)      |

**Notes:** Number of patients (%). The score changes were evaluated as compared with baseline of symptoms before PBE administration.

**Abbreviation:** PBE, pine bark extract.

assessments made by the dermatologists showed that 71% of participants had significant improvement of their age spots.

The percentage of group 1 subjects in part 1 of the low-dose trial who answered that their skin symptoms generally became better after starting oral PBE was around 30%, and this number was much larger than that for subjects who felt that their condition was aggravated after 24 weeks (Table 3A). A similar trend was seen for group 2 patients in the questionnaire, especially those related to facial photoaging symptoms after 24 weeks (Table 3B). In part 2 of the low-dose trial, over 40% of participants in groups 1 and 2 answered that their photoaging symptoms, including solar lentigines and mottled pigmentation, had improved after 18 months as compared with baseline (Table 4).

In part 1 of the low-dose trial, photoaging scores in group 1 as assessed by dermatologists after 12 weeks of PBE were compared with those at the beginning of the study. Scores for solar lentigines, mottled pigmentation, roughness, wrinkles, and swelling showed significant improvement at 12 weeks. Scores for solar lentigines, mottled pigmentation, wrinkles, and swelling were significantly improved (Table 5). Representative clinical images of a typically improved case before and after PBE are shown in Figure 2. In Group 2, there were no significant improvements in scores seen 12 weeks after initial observation as compared with scores before treatment. However, after 24 weeks of treatment, which consisted of a 12-week PBE treatment period following a

**Table 3A** Score assessments of questionnaire survey for group I (phase I, low-dose PBE trial, N = 38)

| Symptoms                        | Improved | No change | Aggravated |
|---------------------------------|----------|-----------|------------|
| Solar lentigines                | 12 (32)  | 24 (65)   | 1 (3)      |
| Mottled pigmentation            | 14 (38)  | 22 (59)   | 1 (3)      |
| Roughness (dry skin)            | 8 (23)   | 26 (74)   | 1 (3)      |
| Roughness (other than dry skin) | 5 (14)   | 28 (78)   | 3 (8)      |
| Wrinkles                        | 1 (3)    | 33 (97)   | 0 (0)      |

**Notes:** Number of patients (%). The score changes were evaluated as compared with baseline of symptoms before PBE administration.

**Abbreviation:** PBE, pine bark extract.



**Table 3B** Score assessments of questionnaire survey for group II (phase I, low-dose PBE trial, N = 39)

| Symptoms                        | Improved | Unchanged | Aggravated |
|---------------------------------|----------|-----------|------------|
| Solar lentigines                | 13 (33)  | 25 (64)   | 1 (3)      |
| Mottled pigmentation            | 10 (26)  | 27 (71)   | 1 (3)      |
| Roughness (dry skin)            | 11 (30)  | 24 (65)   | 2 (5)      |
| Roughness (other than dry skin) | 7 (18)   | 26 (68)   | 5 (13)     |
| Wrinkles                        | 4 (11)   | 31 (84)   | 2 (5)      |

**Notes:** Number of patients (%). The score changes were evaluated as compared with baseline of symptoms before PBE administration.

**Abbreviation:** PBE, pine bark extract.

12-week observation-only period, scores for solar lentigines, mottled pigmentation, and roughness had significantly improved (Table 5).

By comparing the scores between the two groups in part 1 of the low-dose trial, 12 weeks after the initial observation, scores for solar lentigines and skin roughness in part 1 showed significant improvement over those in group 2 (Table 5) during part 2 of the low-dose trial. All 21 cases showed significantly better scores for solar lentigines, mottled pigmentation, roughness, wrinkles, and swelling compared with those at the end of part 1 (Table 6). For part 1 of the low-dose trial, the overall rating for the therapeutic index achieved with low-dose PBE is summarized in Table 7A. An efficacy rating of slightly improved or better was recorded for 87% of subjects in group 1 and 72% in group 2. In part 2 of the trial, significant overall improvements were recorded for all 21 subjects (Table 7B).

## Objective measurements

### Time course of melanin pigmentation in age spots

The melanin index was calculated from the L\*a\*b\* values for each digital image of an age spot. In the high-dose trial, the average melanin index of the age spots gradually decreased from baseline over the 12 weeks. A significant decrease in average melanin index scores at weeks 4 and 12 was confirmed using the Tukey–Kramer method (Figure 3). Twenty-one of the 88 subjects were followed in the low-dose trial. A sig-

**Table 4** Score assessment of questionnaire survey for 18-month PBE administration (phase II, low-dose PBE trial, N = 21)

| Symptoms                        | Improved | Unchanged | Aggravated |
|---------------------------------|----------|-----------|------------|
| Solar lentigines                | 9 (43)   | 12 (57)   | 0 (0)      |
| Mottled pigmentation            | 9 (43)   | 10 (48)   | 1 (5)      |
| Roughness (dry skin)            | 8 (38)   | 10 (48)   | 1 (5)      |
| Roughness (other than dry skin) | 4 (19)   | 12 (48)   | 2 (10)     |
| Wrinkles                        | 4 (19)   | 16 (76)   | 0 (0)      |

**Note:** Number of patients (%).

**Abbreviation:** PBE, pine bark extract.

**Table 5** Physical examination scores (phase I, low-dose PBE trial)

| Symptoms             | Group | Baseline  | 12 weeks                 | 24 weeks               |
|----------------------|-------|-----------|--------------------------|------------------------|
| Solar lentigines     | I     | 2.8 (0.8) | 2.3 (0.6) <sup>c,d</sup> | 2.3 (0.5) <sup>c</sup> |
|                      | II    | 2.7 (0.7) | 2.7 (0.7)                | 2.4 (0.8) <sup>b</sup> |
| Mottled pigmentation | I     | 2.5 (0.6) | 2.1 (0.5) <sup>c</sup>   | 1.9 (0.4) <sup>c</sup> |
|                      | II    | 2.2 (0.7) | 2.2 (0.6)                | 1.9 (0.6) <sup>a</sup> |
| Roughness            | I     | 2.2 (0.7) | 1.8 (0.6) <sup>a,d</sup> | 1.9 (0.6)              |
|                      | II    | 1.9 (0.8) | 2.1 (0.8)                | 1.5 (0.6) <sup>a</sup> |
| Wrinkles             | I     | 2.2 (0.7) | 2.0 (0.6) <sup>a</sup>   | 1.9 (0.6) <sup>b</sup> |
|                      | II    | 2.1 (0.5) | 2.1 (0.5)                | 2.0 (0.5)              |
| Swelling             | I     | 1.4 (0.8) | 1.3 (0.5) <sup>a</sup>   | 1.2 (0.4) <sup>a</sup> |
|                      | II    | 1.4 (0.6) | 1.4 (0.6)                | 1.3 (0.4)              |

**Notes:** Mean score (SD). The efficacy of PBE was assessed by analyzing the change from baseline scores. Reliability was assessed by Wilcoxon signed rank test. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ . Reliability was assessed by Mann–Whitney U test between group I and group II. <sup>d</sup> $P < 0.05$  (group I vs group II).

**Abbreviation:** PBE, pine bark extract.


nificant decrease in average melanin index was observed in both groups, with the melanin index scores in group 1 being significantly lower than at baseline between weeks 8 and 24 ( $P < 0.05$ ), while in group 2, mean melanin index scores were significantly decreased between weeks 16 and 24 (week 16 corresponds to 4 weeks after starting PBE in group 2, Figure 4A and B).

### Effects of PBE on facultative facial skin color

During parts 1 and 2 of the low-dose trial, the whitening effects of PBE on facultative facial skin color were evaluated by average ITA degrees chronologically obtained from a colorimetric assay of forehead skin color. Although the ITA values fluctuated in groups 1 and 2 throughout the study, the average ITA values did not show an overall trend towards lighter values with respect to facial complexion (Figure 5).

### Effects of PBE on corneocyte size

We found a statistically significant reduction in the size of corneocytes in the surface layers of the skin during PBE

**Figure 2** Before (left) and 6 months after (right) treatment of photodamaged skin with oral pine bark extract.

**Table 6** Physical examination scores (phase II, low-dose PBE trial, N = 21)

| Symptoms             | Baseline  | 24 weeks               | 18 months              |
|----------------------|-----------|------------------------|------------------------|
| Solar lentigines     | 2.8 (0.8) | 2.1 (0.4) <sup>b</sup> | 1.9 (0.3) <sup>c</sup> |
| Mottled pigmentation | 2.3 (0.6) | 1.8 (0.4) <sup>b</sup> | 1.6 (0.5) <sup>b</sup> |
| Roughness            | 2.0 (0.9) | 1.5 (0.6) <sup>a</sup> | 1.3 (0.5) <sup>b</sup> |
| Wrinkles             | 1.6 (0.7) | 1.4 (0.5)              | 1.3 (0.5) <sup>a</sup> |
| Swelling             | 2.0 (0.8) | 1.7 (0.7) <sup>a</sup> | 1.6 (0.5) <sup>a</sup> |

**Notes:** Mean score (SD). The efficacy of PBE was assessed by analyzing the change from baseline scores. Reliability was assessed by Wilcoxon signed rank test. <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01, <sup>c</sup>P < 0.001.

**Abbreviation:** PBE, pine bark extract.

administration for longer than 5 months, corresponding to the latter periods of parts 1 and 2 in the low-dose trial. This suggests that PBE helped to repair existing skin damage, considering that corneocyte size usually increases with aging (Figure 6).

## Safety and tolerability

In the high-dose trial, mean corpuscular volume demonstrated a significant change of values after 12 weeks, but the change was within the normal range. No other hematological parameters showed significant changes (Table 8A). In the low-dose trial, mean corpuscular hemoglobin showed a significant change of values in group 2 after 24 weeks, but this value change was within the normal range. No other data showed significant changes (Table 8B).

In the high-dose trial, blood chemistry tests demonstrated significant changes in serum sodium and chloride after 12 weeks of treatment with PBE. There were no other significant changes in blood chemistry parameters (Table 9A).

Significant changes were observed in aspartate aminotransferase in group 1 in the low-dose trial, 24 weeks after oral administration. In group 2, after 15–18 months of treatment with PBE, serum potassium concentrations changed significantly. However, these were both minor fluctuations within the normal range. Other test values, including glycemic control and plasma lipoprotein profile, did not show any significant changes at 18 months (Table 9B). Urine examination was entirely normal (data not shown).

**Table 7A** Overall efficacy rate after 24-week low-dose PBE administration (phase I, low-dose PBE trial)

| Outcome             | Group I | Group II |
|---------------------|---------|----------|
| Markedly improved   | 1 (3)   | 1 (3)    |
| Moderately improved | 16 (42) | 9 (23)   |
| Slightly improved   | 16 (42) | 18 (46)  |
| Unchanged           | 5 (13)  | 11 (28)  |
| Aggravated          | 0 (0)   | 0 (0)    |
| Total               | 38      | 39       |

**Note:** Number of patients (%).

**Abbreviation:** PBE, pine bark extract.

**Table 7B** Overall efficacy rate after 18-month low-dose PBE administration (phase II, low-dose PBE trial)

| Outcome             |         |
|---------------------|---------|
| Markedly improved   | 1 (5)   |
| Moderately improved | 15 (71) |
| Slightly improved   | 5 (24)  |
| Unchanged           | 0 (0)   |
| Aggravated          | 0 (0)   |
| Total               | 21      |


**Note:** Number of patients (%).

**Abbreviation:** PBE, pine bark extract.


No significant changes in body weight or body fat percentage were observed during the test period (data not shown). No adverse events were reported during the study, and the tolerability of PBE was deemed to be acceptable. PBE was considered to be systemically safe based on hematology and biochemistry. Although slight but significant fluctuations in the data were observed for some parameters, all values were within the normal biological ranges.

## Discussion

We examined the efficacy of PBE in the treatment of photodamaged facial skin, and significant improvement was suggested from multiple dermatological score assessments during this study. A subject questionnaire concerning subjective facial symptoms demonstrated that a relatively large number of subjects felt that the roughness of their facial skin had improved in the high-dose trial. Although improvement in age spots was only recognized by a relatively small number of subjects in the high-dose trial, detailed evaluation of digital images revealed that 71% of participants had improvement of their age spots, albeit to a varying extent. In part 1 of the

**Figure 3** The melanin index was significantly decreased after 4 and 12 weeks of oral administration of pine bark extract 100 mg/day.

**Notes:** The melanin index was calculated according to the method reported by Yamamoto et al.<sup>31</sup> Values are expressed as the mean ± standard deviation. \*P < 0.05 (Tukey–Kramer method), n = 24.



**Figure 4** Time course of mean melanin index changes in age spots in group 1 (A) and group 2 (B).


**Notes:** A significant decrease in melanin index was seen after 4–8 weeks of oral pine bark extract 40 mg/day. Melanin index scores were calculated according to the method reported by Yamamoto et al.<sup>31</sup> Values are expressed as the mean  $\pm$  standard deviation. \* $P < 0.05$  (Tukey–Kramer method),  $n = 38$  (group 1),  $n = 39$  (group 2).

low-dose trial, there was significant improvement in scores for solar lentigines, mottled pigmentation, skin roughness, and swelling only when subjects were on treatment with PBE. Further, subjects treated with PBE had significantly lower scores for solar lentigines and skin roughness when compared

with the untreated patients. Therefore, we consider that both the high-dose and low-dose arms in this study demonstrate a similar trend of improvement in symptoms of photodamaged facial skin. Further significant improvements were seen during the long-term 18-month study (part 2 of the low-dose trial) in almost every photoaging score. This improvement was maintained and enhanced by continuous administration of PBE over a long period. Finally, 72% of the subjects receiving PBE for 12 weeks (group 2) showed improvement versus 87% of those receiving PBE for 24 weeks (group 1). All subjects who completed treatment with PBE for 15–18 months showed improvement in symptoms. In line with the score assessment results, objective biophysical measurements demonstrated a significant gradual decrease in average melanin index during treatment with PBE in both trials.

In an earlier safety evaluation, PBE showed excellent overall tolerability without any side effects.<sup>33</sup> Health concerns about prolonged administration of OPCs, such as iron and/or methionine deficiency,<sup>34</sup> were ruled out after it was found that there was no abnormal nutritional sequelae, including iron deficiency anemia, elevated cholesterol readings, or liver damage.


In an earlier study of treatment of photoaged skin with oral polyphenols,<sup>35</sup> a popular polyphenol-rich green tea extract containing (–)-epigallocatechin gallate (EGCG) was used. Although facial photoaging scores improved on treatment with the green tea extract for the first 12 months, there was no significant antiphotaging effect after 24 months of



**Figure 5** Facultative skin color was assessed using a colorimeter followed by individual typology angle value calculation.

**Notes:** The Mann–Whitney U test was used to determine differences between baseline and after treatment with pine bark extract. There are no significant differences between baseline and following treatment with pine bark extract ( $P > 0.05$ ),  $n = 21$ .

**Abbreviation:** ITA, individual typology angle.



**Figure 6** Time course of corneocyte size changes measured by a planimetric method during pine bark extract administration.

**Notes:** The mean surface size of the corneocytes decreased significantly after 5 months of treatment with pine bark extract. Values are expressed as the mean  $\pm$  standard deviation of corneocyte surface area. \* $P < 0.05$  (unpaired *t*-test); \*\* $P < 0.05$  (Mann–Whitney U test),  $n = 21$ .

treatment. In contrast, gradual improvement of photoaging scores even at 18 months was confirmed in our PBE trial. Demographic diversity in subject age and race might account for the different results seen in these two studies. The mean age of the subjects in the previous study was around 12 years older than in our study, so a less favorable outcome would be expected because of the exponential decline of intrinsic antioxidative potency in the elderly. Our findings in Japanese women might be positively biased by a racial difference, ie, age spots in East Asians often appear as early as in the

20 s and 30 s, while age spots in Caucasians tend to become apparent between the ages of 50 and 60 years.<sup>36</sup>

The EGCG used in the previous trial was a prodelphinidin-type flavonoid that also acts as a pro-oxidant, with production of active superoxide radical anions.<sup>37</sup> EGCG is beneficial in chemoprevention because of its pro-oxidant nature, and it works as a PI3K/AKT/mTOR pathway inhibitor, triggering apoptosis of cancer cells.<sup>38,39</sup> However, this action might cause a pro/antioxidant cellular imbalance and aggravate photoaging of the skin. In contrast, such undesirable effects on the skin are much less likely to occur with (–)-epicatechin, (+)-catechin, or procyanidin-type polymers, that are the main constituents of the OPCs in PBE.

In the skin, PBE has been found to protect capillary walls<sup>40</sup> and to inhibit matrix metalloproteinases.<sup>41</sup> Direct assessment of the antioxidant effects of PBE by electron spin resonance spectroscopy showed that PBE had significant antioxidant effects on the facial skin of ultraviolet B-irradiated hairless mice *in vivo*.<sup>1</sup> OPCs have also been reported to be effective inhibitors of tyrosinase in skin-derived melanocytes and in the hyperpigmented skin of ultraviolet-irradiated mice and guinea pigs.<sup>42–45</sup> Oral OPC supplements are expected to have desirable effects on photoaging because they promote tissue elasticity, help heal microinjuries, reduce bruising and swelling by strengthening blood vessels, prevent postinflammatory skin pigmentation, restore dermal collagen, and improve the

**Table 8A** Results of hematology in 24 evaluated cases (high-dose PBE trial, 12-week administration)

| Parameter (units)                      | Reference ranges | Baseline         | 12 weeks         |
|--|------------------|------------------|------------------|
| Red blood cells ( $10^4/\mu\text{L}$ ) | 370–510          | $420.0 \pm 31.2$ | $420.2 \pm 42.4$ |
| Hemoglobin (g/dL)                      | 11–15.5          | $13.0 \pm 0.7$   | $12.8 \pm 1.0$   |
| Hematocrit (%)                         | 34–46            | $37.9 \pm 2.9$   | $38.1 \pm 5.1$   |
| MCV (fL)                               | 80–103           | $90.6 \pm 6.1$   | $90.9 \pm 6.8^a$ |
| MCH (pg)                               | 26–35            | $30.6 \pm 2.9$   | $30.5 \pm 3.3$   |
| MCHC (%)                               | 31–36            | $33.7 \pm 1.4$   | $33.5 \pm 1.5$   |
| Platelets ( $10^4/\mu\text{L}$ )       | 12–34            | $23.9 \pm 5.7$   | $24.8 \pm 5.5$   |
| White blood cells ( $\mu\text{L}$ )    | 3500–9100        | $5276 \pm 1780$  | $5375 \pm 1990$  |
| Neutrophil (%)                         | 41–73            | $59.8 \pm 9.3$   | $60.5 \pm 9.2$   |
| Lymphocyte (%)                         | 20–50            | $32.0 \pm 7.0$   | $31.4 \pm 7.5$   |
| Eosinophil (%)                         | 0–9              | $2.3 \pm 1.4$    | $2.4 \pm 1.5$    |

**Notes:** Mean  $\pm$  SD. <sup>a</sup> $P < 0.05$ , Student's *t*-test for paired values, 2-tailed.

**Abbreviations:** PBE, pine bark extract. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration.



**Table 8B** Results of hematology in 21 evaluated cases (phase II, low-dose PBE trial, 18-month administration)

| Parameter (units)               | Reference range | Group | Baseline         | 24 weeks                    | 18 months        |
|---------------------------------|-----------------|-------|------------------|-----------------------------|------------------|
| Red cell ( $10^6/\mu\text{L}$ ) | 370–510         | I     | 434.1 $\pm$ 24.4 | 426.8 $\pm$ 32.4            | 428.7 $\pm$ 34.1 |
|                                 |                 | II    | 422.7 $\pm$ 29.1 | 425.5 $\pm$ 23.3            | 425.5 $\pm$ 22.4 |
| Hemoglobin (g/dL)               | 11–15.5         | I     | 13.0 $\pm$ 0.7   | 12.8 $\pm$ 1.0              | 12.8 $\pm$ 1.1   |
|                                 |                 | II    | 12.7 $\pm$ 0.7   | 13.0 $\pm$ 0.7              | 12.9 $\pm$ 0.7   |
| Hematocrit (%)                  | 34–46           | I     | 40.6 $\pm$ 2.0   | 39.3 $\pm$ 2.9              | 39.7 $\pm$ 3.4   |
|                                 |                 | II    | 40.7 $\pm$ 2.6   | 40.0 $\pm$ 2.1              | 40.5 $\pm$ 2.7   |
| MCV (fL)                        | 80–103          | I     | 93.7 $\pm$ 4.5   | 92.2 $\pm$ 4.1              | 92.6 $\pm$ 4.8   |
|                                 |                 | II    | 96.3 $\pm$ 2.5   | 94.1 $\pm$ 2.5              | 95.2 $\pm$ 4.5   |
| MCH (pg)                        | 26–35           | I     | 30.1 $\pm$ 1.4   | 30.1 $\pm$ 1.5              | 29.9 $\pm$ 1.8   |
|                                 |                 | II    | 30.0 $\pm$ 1.3   | 30.6 $\pm$ 1.1 <sup>a</sup> | 30.3 $\pm$ 0.9   |
| MCHC (%)                        | 31–36           | I     | 32.2 $\pm$ 1.1   | 32.6 $\pm$ 1.3              | 32.3 $\pm$ 0.9   |
|                                 |                 | II    | 31.2 $\pm$ 1.1   | 32.6 $\pm$ 0.5              | 31.9 $\pm$ 0.7   |
| Platelet ( $10^4/\mu\text{L}$ ) | 12–34           | I     | 27.5 $\pm$ 8.0   | 27.0 $\pm$ 5.3              | 27.3 $\pm$ 5.3   |
|                                 |                 | II    | 26.4 $\pm$ 3.6   | 26.7 $\pm$ 3.8              | 26.4 $\pm$ 4.1   |
| White cell ( $\mu\text{L}$ )    | 3500–9100       | I     | 6193 $\pm$ 1876  | 6060 $\pm$ 1558             | 6253 $\pm$ 1799  |
|                                 |                 | II    | 5883 $\pm$ 1222  | 5916 $\pm$ 1052             | 5283 $\pm$ 768   |
| Neutrophil (%)                  | 41–73           | I     | 58.9 $\pm$ 6.9   | 58.7 $\pm$ 9.8              | 61.1 $\pm$ 10.3  |
|                                 |                 | II    | 59.0 $\pm$ 7.1   | 59.2 $\pm$ 4.7              | 58.5 $\pm$ 4.5   |
| Lymphocyte (%)                  | 20–50           | I     | 31.9 $\pm$ 5.7   | 32.8 $\pm$ 9.4              | 30.7 $\pm$ 9.6   |
|                                 |                 | II    | 31.8 $\pm$ 5.9   | 32.2 $\pm$ 6.1              | 34.3 $\pm$ 2.4   |
| Eosinophil (%)                  | 0–9             | I     | 3.3 $\pm$ 2.5    | 2.7 $\pm$ 1.8               | 2.9 $\pm$ 1.9    |
|                                 |                 | II    | 3.8 $\pm$ 2.6    | 3.5 $\pm$ 2.5               | 2.7 $\pm$ 2.4    |

**Notes:** Mean  $\pm$  SD. <sup>a</sup>P < 0.01, Student's *t*-test for paired values, 2-tailed.

**Abbreviations:** PBE, pine bark extract; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration.

peripheral circulation.<sup>46,47</sup> In fact, OPCs from grape seeds have previously been reported to improve melasma to a significant extent.<sup>48</sup>

A white complexion is a highly desirable symbol of beauty among Asian women, who believe that it is powerful enough to hide a number of faults. PBE did not modify facultative skin color in our trial, suggesting that the skin

lightening elicited by PBE is confined to solar lentigines that appear with chronic inflammation, and can persist long after exposure to ultraviolet light. Recent profiling of solar lentigines with cDNA microarrays and immunohistochemical assays revealed a number of upregulated genes for the enzymes that synthesize arachidonic acid, as well as melanogenic and inflammatory genes in those lesions.<sup>49</sup>

Nuclear factor E2-related factor 2 (Nrf2)/antioxidative response element-mediated phase 2 detoxifying/antioxidant enzymes are induced by OPCs,<sup>50</sup> so OPC-activated Nrf2 confers protection against ultraviolet-induced skin inflammation.<sup>51</sup> OPCs are expected to be potent suppressors of expression or activity of genes in the melanogenic, inflammatory, and arachidonic acid-synthesizing categories downstream of Nrf2.<sup>52,53</sup> Interestingly, the arachidonate 12-lipoxygenase gene (*ALOX*), which is locally upregulated in solar lentigines,<sup>49</sup> may be downregulated by treatment with oral OPCs in mice.<sup>54</sup>

Another possible lightening mechanism, ie, acceleration of epidermal turnover, is suggested by the significant reduction in corneocyte size by PBE. PBE induces a gentle yet sufficiently effective exfoliating action in the skin to promote release of excess epidermal melanin deposition.<sup>55,56</sup>

**Table 9A** Results of blood chemistry in 24 evaluated cases (high dose PBE trial, 12-week administration)

| Parameter (units)                 | Reference range | Baseline         | 12 weeks                      |
|-----------------------------------|-----------------|------------------|-------------------------------|
| Total cholesterol (mg/dL)         | 150–219         | 186.4 $\pm$ 39.2 | 185.1 $\pm$ 30.6 <sup>a</sup> |
| HDL-C (mg/dL)                     | 40–96           | 70.0 $\pm$ 14.3  | 63.1 $\pm$ 12.3               |
| Triglycerides (mg/dL)             | 50–149          | 78.4 $\pm$ 40.1  | 82.3 $\pm$ 56.1               |
| Aspartate aminotransferase (IU/l) | 10–40           | 17.4 $\pm$ 3.0   | 16.6 $\pm$ 1.8                |
| Alanine aminotransferase (IU/l)   | 5–40            | 13.9 $\pm$ 6.4   | 15.9 $\pm$ 8.3                |
| Blood urea nitrogen (mg/dL)       | 6–20            | 11.7 $\pm$ 3.3   | 11.0 $\pm$ 2.8                |
| Na <sup>+</sup> (mEq/l)           | 136–147         | 140.5 $\pm$ 1.7  | 139.1 $\pm$ 1.0 <sup>b</sup>  |
| K <sup>+</sup> (mEq/l)            | 3.6–5           | 4.2 $\pm$ 0.4    | 4.1 $\pm$ 0.4                 |
| Cl <sup>-</sup> (mEq/l)           | 98–109          | 104.2 $\pm$ 1.9  | 103.5 $\pm$ 1.6 <sup>a</sup>  |

**Notes:** Mean  $\pm$  SD. <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01, Student's *t*-test for paired values, 2-tailed.

**Abbreviations:** PBE, pine bark extract; HDL-C, high-density lipoprotein cholesterol.

**Table 9B** Results of blood chemistry in 21 evaluated cases (phase II, low-dose PBE trial, 18-month administration)

| Parameter (units)                 | Reference range | Group | Baseline     | 24 weeks                | 18 months              |
|-----------------------------------|-----------------|-------|--------------|-------------------------|------------------------|
| Total cholesterol (mg/dL)         | 150–219         | I     | 198.1 ± 33.2 | 192.9 ± 29.2            | 192.9 ± 32.5           |
|                                   |                 | II    | 178.0 ± 36.0 | 171.5 ± 39.9            | 180.2 ± 40.3           |
| HDL-C (mg/dL)                     | 40–96           | I     | 68.1 ± 15.8  | 65.9 ± 10.9             | 68.7 ± 14.6            |
|                                   |                 | II    | 75.2 ± 11.4  | 72.2 ± 13.8             | 73.8 ± 14.2            |
| LDL-C (mg/dL)                     | 70–139          | I     | 113.0 ± 23.8 | 113.1 ± 27.0            | 108.4 ± 23.3           |
|                                   |                 | II    | 88.7 ± 35.9  | 89.8 ± 32.9             | 92.2 ± 28.4            |
| Triglycerides (mg/dL)             | 50–149          | I     | 87.9 ± 69.6  | 88.3 ± 41.0             | 82.3 ± 41.6            |
|                                   |                 | II    | 54.5 ± 13.2  | 69.8 ± 37.0             | 58.5 ± 20.3            |
| Free fat acid (mEq/l)             | 0.14–0.85       | I     | 0.35 ± 0.18  | 0.39 ± 0.31             | 0.44 ± 0.34            |
|                                   |                 | II    | 0.44 ± 0.22  | 0.32 ± 0.15             | 0.34 ± 0.26            |
| Aspartate aminotransferase (IU/l) | 10–40           | I     | 19.3 ± 4.5   | 16.6 ± 1.8 <sup>a</sup> | 17.2 ± 3.6             |
|                                   |                 | II    | 18.8 ± 2.4   | 19.5 ± 7.7              | 15.2 ± 2.2             |
| Alanine aminotransferase (IU/l)   | 5–40            | I     | 14.3 ± 6.8   | 11.3 ± 3.8              | 12.5 ± 4.8             |
|                                   |                 | II    | 14.7 ± 4.4   | 16.2 ± 6.8              | 11.5 ± 2.7             |
| Blood urea nitrogen (mg/dL)       | 6–20            | I     | 12.6 ± 2.8   | 13.4 ± 4.2              | 13.2 ± 3.7             |
|                                   |                 | II    | 12.8 ± 2.1   | 12.3 ± 1.3              | 12.1 ± 2.5             |
| Na <sup>+</sup> (mEq/l)           | 136–147         | I     | 139.9 ± 2.2  | 140.1 ± 1.2             | 139.5 ± 1.6            |
|                                   |                 | II    | 138.7 ± 1.5  | 139.3 ± 1.8             | 139.7 ± 0.5            |
| K <sup>+</sup> (mEq/l)            | 3.6–5           | I     | 4.3 ± 0.7    | 4.3 ± 0.5               | 4.1 ± 0.6              |
|                                   |                 | II    | 4.4 ± 0.5    | 4.3 ± 0.6               | 3.9 ± 0.3 <sup>b</sup> |
| Cl <sup>-</sup> (mEq/l)           | 98–109          | I     | 104.0 ± 3.4  | 104.9 ± 1.8             | 104.6 ± 2.4            |
|                                   |                 | II    | 103.8 ± 1.8  | 104.8 ± 2.0             | 104.3 ± 3.2            |
| Iron (μg/dL)                      | 48–154          | I     | 81.5 ± 41.0  | 91.5 ± 40.1             | 86.9 ± 54.8            |
|                                   |                 | II    | 84.0 ± 50.8  | 98.7 ± 19.0             | 88.8 ± 34.8            |
| Ferritin (ng/mL)                  | 7–110           | I     | 20.2 ± 18.0  | 15.1 ± 18.7             | 19.5 ± 17.0            |
|                                   |                 | II    | 29.5 ± 15.4  | 28.7 ± 15.7             | 33.4 ± 22.9            |

**Notes:** Mean ± SD. <sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01, Student's t-test for paired values, 2-tailed.

**Abbreviations:** PBE, pine bark extract; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

## Conclusion

Oral administration of French maritime PBE effectively reduces facial symptoms of photoaging. Long-term administration of PBE is safe and useful for improving the appearance of photodamaged facial skin.

## Disclosure

This research was supported by a research grant from Toyo Shinyaku Co, Ltd, Tosu City, Saga, Japan. Toyo Shinyaku Co, Ltd, provided study tablets similar to the TOYO-PBE tablets marketed in the US. Otherwise, the authors report no conflict of interest in this work.

## References

- Yoshida A, Yoshino F, Tsubata M, Ikeguchi M, Nakamura T, Lee MC. Direct assessment by electron spin resonance spectroscopy of the antioxidant effects of French maritime pine bark extract in the maxillofacial region of hairless mice. *J Clin Biochem Nutr*. 2011;49(2):79–86.
- Masquelier J, Michaud J, Laparra J, Dumon MC. Flavonoids and pycnogenols. *Int J Vitam Nutr Res*. 1979;49(3):307–311.
- Hammerstone JF, Lazarus SA, Mitchell AE, Rucker R, Schmitz HH. Identification of procyanidins in cocoa (*Theobroma cacao*) and chocolate using high-performance liquid chromatography/mass spectrometry. *J Agric Food Chem*. 1999;47(2):490–496.
- Cansfield PE, Marquardt RR, Campbell LD. Condensed proanthocyanidins of fababeans. *J Sci Food Agric*. 1980;31(8):802–812.
- Aneja R, Hake PW, Burroughs TJ, Denenberg AG, Wong HR, Zingarelli B. Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. *Mol Med*. 2004;10(1–6):55–62.
- Diebolt M, Laflamme K, Labbe R, Auger FA, Germain L, Andriantsitohaina R. Polyphenols modulate calcium-independent mechanisms in human arterial tissue-engineered vascular media. *J Vasc Surg*. 2007;46(4):764–772.
- Maimoona A, Naeem I, Saddiqe Z, Jameel K. A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. *J Ethnopharmacol*. 2011;133(2):261–277.
- Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. *Arch Dermatol*. 2002;138(11):1462–1470.
- Gasperlin M, Gosenca M. Main approaches for delivering antioxidant vitamins through the skin to prevent skin ageing. *Expert Opin Drug Deliv*. 2011;8(7):905–919.
- Dreher F, Maibach H. Protective effects of topical antioxidants in humans. *Curr Probl Dermatol*. 2001;29:157–164.
- Junqueira VB, Barros SB, Chan SS, et al. Aging and oxidative stress. *Mol Aspects Med*. 2004;25(1–2):5–16.
- Lane N. A unifying view of ageing and disease: the double-agent theory. *J Theor Biol*. 2003;225(4):531–540.
- Lu CY, Lee HC, Fahn HJ, Wei YH. Oxidative damage elicited by imbalance of free radical scavenging enzymes is associated with large-scale mtDNA deletions in aging human skin. *Mutat Res*. 1999;423(1–2):11–21.
- Stadtman ER, Levine RL. Protein oxidation. *Ann NY Acad Sci*. 2000;899:191–208.

15. Nouveau-Richard S, Yang Z, Mac-Mary S, et al. Skin ageing: a comparison between Chinese and European populations. A pilot study. *J Dermatol Sci*. 2005;40(3):187–193.
16. Holzle E. Pigmented lesions as a sign of photodamage. *Br J Dermatol*. 1992;127 Suppl 41:48–50.
17. Gillbro JM, Olsson MJ. The melanogenesis and mechanisms of skin-lightening agents – existing and new approaches. *Int J Cosmet Sci*. 2011;33(3):210–221.
18. Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. *J Am Acad Dermatol*. 2003;48(1):1–19.
19. Eberlein-Konig B, Placzek M, Przybilla B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E). *J Am Acad Dermatol*. 1998;38(1):45–48.
20. Stahl W, Sies H. Carotenoids and flavonoids contribute to nutritional protection against skin damage from sunlight. *Mol Biotechnol*. 2007;37(1):26–30.
21. Mittal A, Elmetts CA, Katiyar SK. CD11b+ cells are the major source of oxidative stress in UV radiation-irradiated skin: possible role in photoaging and photocarcinogenesis. *Photochem Photobiol*. 2003;77(3):259–264.
22. Afaq F, Mukhtar H. Botanical antioxidants in the prevention of photocarcinogenesis and photoaging. *Exp Dermatol*. 2006;15(9):678–684.
23. Drieling RL, Gardner CD, Ma J, Ahn DK, Stafford RS. No beneficial effects of pine bark extract on cardiovascular disease risk factors. *Arch Intern Med*. 2010;170(17):1541–1547.
24. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. *Drug Saf*. 2008;31(6):469–484.
25. Frank J, George TW, Lodge JK, et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. *J Nutr*. 2009;139(1):58–62.
26. Galati G, Lin A, Sultan AM, O'Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. *Free Radic Biol Med*. 2006;40(4):570–580.
27. Federico A, Tiso A, Loguercio C. A case of hepatotoxicity caused by green tea. *Free Radic Biol Med*. 2007;43(3):474.
28. Jimenez-Saenz M, Martinez-Sanchez C. Green tea extracts and acute liver failure: the need for caution in their use and diagnostic assessment. *Liver Transpl*. 2007;13(7):1067.
29. Jimenez-Saenz M, Martinez-Sanchez M del C. Acute hepatitis associated with the use of green tea infusions. *J Hepatol*. 2006;44(3):616–617.
30. Sugaya K, Igarashi M, Kojima Y, Tsubata M, Nagaoka I. Evaluation of the effect of flavangenol on serum lipid peroxide levels and development of atherosclerosis in spontaneously hyperlipidemic B6. KOR-Apoeshl mice. *Int J Mol Med*. 2011;27(1):33–38.
31. Yamamoto T, Takiwaki H, Arase S, Ohshima H. Derivation and clinical application of special imaging by means of digital cameras and Image J freeware for quantification of erythema and pigmentation. *Skin Res Technol*. 2008;14(1):26–34.
32. Park SB, Suh DH, Youn JI. A long-term time course of colorimetric evaluation of ultraviolet light-induced skin reactions. *Clin Exp Dermatol*. 1999;24(4):315–320.
33. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. *Int J Clin Pharmacol Ther*. 2002;40(4):158–168.
34. Mennen LI, Walker R, Bennetau-Pelissero C, Scalbert A. Risks and safety of polyphenol consumption. *Am J Clin Nutr*. 2005;81(Suppl 1):326S–329S.
35. Chiu AE, Chan JL, Kern DG, Kohler S, Rehms WE, Kimball AB. Double-blinded, placebo-controlled trial of green tea extracts in the clinical and histologic appearance of photoaging skin. *Dermatol Surg*. 2005;31(7 Pt 2):855–860.
36. Goh SH. The treatment of visible signs of senescence: the Asian experience. *Br J Dermatol*. 1990;122 Suppl 35:105–109.
37. Meagher LP, Spencer P, Lane GA, Sivakumaran S, Fraser K. What do green tea, grapes seeds, and docks have in common? *Chem N Z*. 2005;69(3):4.
38. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, Nakashima K. PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. *FEBS Lett*. 2003;546(2–3):181–184.
39. Van Aller GS, Carson JD, Tang W, et al. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. *Biochem Biophys Res Commun*. 2011;406(2):194–199.
40. Belcaro G, Cesarone MR, Ricci A, et al. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. *Clin Appl Thromb Hemost*. 2006;12(4):440–444.
41. Grimm T, Schafer A, Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). *Free Radic Biol Med*. 2004;36(6):811–822.
42. Shoji T, Masumoto S, Moriichi N, et al. Procyanidin trimers to pentamers fractionated from apple inhibit melanogenesis in B16 mouse melanoma cells. *J Agric Food Chem*. 2005;53(15):6105–6111.
43. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. *J Investig Dermatol Symp Proc*. 2008;13(1):20–24.
44. Hanamura T, Uchida E, Aoki H. Skin-lightening effect of a polyphenol extract from Acerola (*Malpighia emarginata* DC) fruit on UV-induced pigmentation. *Biosci Biotechnol Biochem*. 2008;72(12):3211–3218.
45. Yamakoshi J, Otsuka F, Sano A, et al. Lightening effect on ultraviolet-induced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. *Pigment Cell Res*. 2003;16(6):629–638.
46. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*. 2005;81(Suppl 1):230S–242S.
47. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. *Am J Clin Nutr*. 2005;81(Suppl 1):243S–255S.
48. Yamakoshi J, Sano A, Tokutake S, et al. Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. *Phytother Res*. 2004;18(11):895–899.
49. Aoki H, Moro O, Tagami H, Kishimoto J. Gene expression profiling analysis of solar lentigo in relation to immunohistochemical characteristics. *Br J Dermatol*. 2007;156(6):1214–1223.
50. Bak MJ, Jun M, Jeong WS. Procyanidins from wild grape (*Vitis amurensis*) seeds regulate ARE-mediated enzyme expression via Nrf2 coupled with p38 and PI3K/Akt pathway in HepG2 cells. *Int J Mol Sci*. 2012;13(1):801–818.
51. Saw CL, Huang MT, Liu Y, Khor TO, Conney AH, Kong AN. Impact of Nrf2 on UVB-induced skin inflammation/photoprotection and photoprotective effect of sulforaphane. *Mol Carcinog*. 2011;50(6):479–486.
52. Hirota A, Kawachi Y, Yamamoto M, Koga T, Hamada K, Otsuka F. Acceleration of UVB-induced photoaging in nrf2 gene-deficient mice. *Exp Dermatol*. 2011;20(8):664–668.
53. Gescher A, Gerhauser C. Cancer chemopreventive agents in plants – a continuing challenge. *Planta Med*. 2008;74(13):1523–1525.
54. Shen G, Xu C, Hu R, et al. Comparison of (–)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (–/–) mice. *Pharm Res*. 2005;22(11):1805–1820.
55. Iriyama S, Ono T, Aoki H, Amano S. Hyperpigmentation in human solar lentigo is promoted by heparanase-induced loss of heparan sulfate chains at the dermal-epidermal junction. *J Dermatol Sci*. 2011;64(3):223–228.
56. Chen N, Hu Y, Li WH, et al. The role of keratinocyte growth factor in melanogenesis: a possible mechanism for the initiation of solar lentigines. *Exp Dermatol*. 2010;19(10):865–872.

**Clinical Interventions in Aging****Dovepress****Publish your work in this journal**

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, the American Chemical Society's 'Chemical Abstracts Ser-

vice' (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/clinical-interventions-in-aging-journal>